SMILE vs. LASIK Using Contoura With Phorcides

Sponsor
59th Medical Wing (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT05844397
Collaborator
(none)
56
1
2
12
4.7

Study Details

Study Description

Brief Summary

Subjects will undergo SMILE surgery in one eye and LASIK using Contoura with Phorcides on the contralateral eye to correct myopia.

Condition or Disease Intervention/Treatment Phase
  • Device: WaveLight EX500 Excimer Laser System
  • Device: VisuMax Surgical Laser
N/A

Detailed Description

Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo simultaneous SMILE surgery in one eye and LASIK using Contoura with Phorcides on the contralateral eye to correct myopia.The study objective is to compare the 6-month visual outcomes (i.e., visual acuity, contract sensitivity, high order aberrations), quality of vision (i.e., double vision, glare, starburst, halos, etc.) and dry eye symptoms of patients undergoing contralateral LASIK using Contoura with Phorcides and SMILE surgery. Surgical treatment will be randomized so there is a 50% chance to receive SMILE on the right eye and LASIK on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. Visual outcomes and patient self-reported symptoms will be assessed at week 2, month 1, month 3, and month 6.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
56 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective randomized contralateral study.Prospective randomized contralateral study.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Comparison of Clinical Outcomes of SMILE vs. LASIK Using Contoura With Phorcides
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
May 14, 2024
Anticipated Study Completion Date :
May 14, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: LASIK using Contoura with Phorcides

LASIK using Contoura with Phorcides in one eye.

Device: WaveLight EX500 Excimer Laser System
LASIK Refractive Surgery Using Contura with Phorcides

Active Comparator: SMILE

small incision lenticule extraction (SMILE) refractive surgery on the contralateral eye.

Device: VisuMax Surgical Laser
SMILE Refractive Surgery

Outcome Measures

Primary Outcome Measures

  1. Percentage of eyes with Uncorrected Visual Acuity of 20/16 or better at 6-month Post-Op [6-month Post-Op]

    Post-operative uncorrected visual acuity of 20/16 or better measure with ETDRS chart; unit = percentage eyes with Uncorrected Visual Acuity

Secondary Outcome Measures

  1. Change in high contrast visual acuity at 6-month Post-Op [Change from baseline (pre-op) to 6-month Post-Op]

    Change in the mean uncorrected visual acuity (unit = logMAR) measure with ETDRS chart from baseline (pre-op) at 6 months post-op.

  2. Change in refractive error at 6-month Post-Op [Change from baseline (pre-op) to 6-month Post-Op]

    Change in the mean refractive error measure with phoropter (unit = diopters) from baseline (pre-op) at 6 months post-op.

Other Outcome Measures

  1. Change in low contrast visual acuity at 6-month Post-Op [Change from baseline (pre-op) to 6-month Post-Op]

    Change in the mean low contrast visual acuity (unit = logMAR) measure with ETDRS 5% chart from baseline (pre-op) at 6 months post-op.

  2. Change in higher order aberrations at 6-month Post-Op [Changes from baseline (pre-op) to 6-month Post-Op]

    Change in the mean higher order aberrations (unit = root mean square) measure with iDesign 2.0 Refractive Studio from baseline (pre-op) at 6 months post-op.

  3. Change in mean score Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 6-month Post-Op [Changes from baseline (pre-op) to 6-month Post-Op]

    The PROWL-SS is a validated tool to assess self-reported symptoms and satisfaction after refractive surgery. Possible Satisfaction Score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction. Possible Symptoms Score ranges from 1 (extremely bothersome) to 5 (not at all bothersome). Lower value indicates worse symptoms.

  4. Change in mean score Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire at 6-month Post-Op [Changes from baseline (pre-op) to 6-month Post-Op]

    The SPEED is a validated tool to assess self-reported dry eye symptoms. Possible dry eye symptoms score ranges from 0 (never) to 3 (Constant). Higher value indicates worse dry eye symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and Females between the ages of 21 and 50

  • Nearsightedness between -2.00 diopters and -8.00 diopters

  • Have similar levels of nearsightedness in each eye (≤1.5D of difference between eyes)

  • Less than or equal to 3.00 diopters of astigmatism

  • Have similar levels of astigmatism in each eye (≤0.75D of difference between eyes)

  • Total spherical equivalent (SE) of no more than -8.0 D

  • Tricare Prime Beneficiary

  • Residing within 60 miles radius from Lackland AFB

Exclusion Criteria:
  • Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and patients whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns (μm) of corneal stroma from the corneal endothelium.

  • Subjects with active collagen vascular, connective tissue, autoimmune or immunodeficiency diseases

  • Pregnant or nursing females

  • Systemic disease likely to affect wound healing, such as uncontrolled diabetes and severe atopy

  • Any ocular disease such as advanced/uncontrolled glaucoma, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection.

  • 0.25 or 0.50 of manifest astigmatism in either eye

  • Taking the medication Isotretinoin (Accutane) or antimetabolites for any medical condition.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Wilford Hall Ambulatory Surgical Center Lackland Air Force Base Texas United States 78236

Sponsors and Collaborators

  • 59th Medical Wing

Investigators

  • Principal Investigator: Charisma B Evangelista, MD, 59th Medical Wing

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
59th Medical Wing
ClinicalTrials.gov Identifier:
NCT05844397
Other Study ID Numbers:
  • C.2023.052
First Posted:
May 6, 2023
Last Update Posted:
May 6, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by 59th Medical Wing
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2023